Do lower thresholds for diagnosis of gestational diabetes have later benefits for mothers and babies?

Women who develop diabetes in pregnancy are at risk of later type 2 diabetes and heart disease, and their babies are at risk of obesity and later diabetes.

The aim of the GEMS randomised trial is to find out the best way of diagnosing gestational diabetes to improve pregnancy and birth outcomes, but we also need to know if this has any later benefits for the mother or baby.

Objective:

To determine in the GEMS cohort whether different thresholds for diagnosing gestational diabetes alter:

i) Later health of the women

ii) Outcomes of subsequent pregnancies

ii) Growth, health and development of the children.
Other information

Here is more information about the GEMS trial: https://www.auckland.ac.nz/en/liggins/in-the-community/clinical-studies/clinical-studies-pregnancy/gems.html

Who we are:

The Liggins Institute is a world-leading centre for research on fetal and child health, nutrition, development, genome biology and translational and implementation science. Our mission is to improve life-long health through excellent research into the long-term consequences of early life events.

We work across a range of fields to view human health problems from different angles. This unique approach enables us to turn research discoveries into real strategies that will help people to prevent or manage major health problems in the 21st century.

As a research-only institute, we attract some of the best research students and clinical fellows in the world. You’ll be supported by internationally-recognised staff and you’ll benefit from state-of-the-art laboratory facilities and a dedicated clinical research unit.

To learn more about the Liggins Institute visit https://www.auckland.ac.nz/en/liggins.html